title: Anaphylaxis following the use of a plasma-derived immunopurified monoclate-P, and the recombinant Recombinate and Kogenate factor VIII: a therapeutic challenge.
authors.forename: G
authors.initials: G
authors.lastname: Pernod
authors.forename: C
authors.initials: C
authors.lastname: Armari
authors.forename: C
authors.initials: C
authors.lastname: Barro
authors.forename: D
authors.initials: D
authors.lastname: Plantaz
authors.forename: D
authors.initials: D
authors.lastname: Caperan
authors.forename: C
authors.initials: C
authors.lastname: Jacquot
authors.forename: B
authors.initials: B
authors.lastname: Polack
mesh_terms: D000707:Anaphylaxis / Q000139:chemically induced*; D005169:Factor VIII / Q000302:isolation & purification / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; C078147:F8 protein, human; D005169:Factor VIII